Congestive heart failure (CHF) is a physiological condition that has an adverse impact on the pumping efficiency of the cardiac muscles. It characterizes the accumulation of fluid around the heart leading to inefficient pumping. The onset of CHF is marked by the failure of the ventricles to pump sufficient volume of blood to the body organs. This eventually leads to deposition of fluid in the lungs, abdomen, liver, and lower body. CHF is treated by a number of devices that maintain heart rhythm, such as pacemakers, cardiac resynchronization therapy (CRT), implantable cardioverter defibrillators (ICDs), and ventricular assist devices (VADs).
This is primarily attributed to the constantly changing lifestyle habits (such as unhealthy dietary habits, excessive alcohol consumption, smoking, obesity, and lack of physical activity) which make individuals more susceptible to arrhythmia and heart failure. In addition, a number of factors such as the large number of technological advancements in CHF treatment devices, increased adoption rate of these devices, and rising emphasis on early intervention and primary prevention of heart-related disorders are responsible for driving the market. Conversely, stringent government regulations for the approval of CHF treatment devices, high cost of, and high preference to drugs for CHF treatment are some of the factors restraining the market growth.
The global Congestive Heart Failure (CHF) Treatment Devices market was valued at 11000 million US$ in 2018 and will reach 17200 million US$ by the end of 2025, growing at a CAGR of 5.7% during 2019-2025.
This report focuses on Congestive Heart Failure (CHF) Treatment Devices volume and value at global level, regional level and company level. From a global perspective, this report represents overall Congestive Heart Failure (CHF) Treatment Devices market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Congestive Heart Failure (CHF) Treatment Devices in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Congestive Heart Failure (CHF) Treatment Devices manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.
The following manufacturers are covered:
Abiomed
Berlin Heart GmbH
Biotronik SE & Co. KG
Boston Scientific Corporation
HeartWare International
Jarvik Heart
LivaNova PLC
Medtronic
ReliantHeart
St. Jude Medical
Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India
Segment by Type
Cardiac Resynchronization Therapy (CRT)
Implantable Cardioverter Defibrillators (ICDs)
Segment by Application
Left Ventricular Assist Device (LVAD)
Right Ventricular Assist Device (RVAD)
Biventricular Assist Device (BIVAD)
Summary:
Get latest Market Research Reports on Congestive Heart Failure (CHF) Treatment Devices. Industry analysis & Market Report on Congestive Heart Failure (CHF) Treatment Devices is a syndicated market report, published as Global Congestive Heart Failure (CHF) Treatment Devices Market Professional Survey Report 2019. It is complete Research Study and Industry Analysis of Congestive Heart Failure (CHF) Treatment Devices market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.